Compounds > nafamostat
Page last updated: 2024-10-31

nafamostat and Blood Loss, Postoperative

nafamostat has been researched along with Blood Loss, Postoperative in 1 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kaminishi, Y1
Hiramatsu, Y1
Watanabe, Y1
Yoshimura, Y1
Sakakibara, Y1

Trials

1 trial available for nafamostat and Blood Loss, Postoperative

ArticleYear
Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
    The Annals of thoracic surgery, 2004, Volume: 77, Issue:2

    Topics: Aged; Aprotinin; Benzamidines; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Drug Therap

2004